Remove analyst-stock-ratings
article thumbnail

The Rise of “Sell-Side Activism”: Why It’s Happening and How to Respond

Harvard Corporate Governance

They may be more surprised to hear about an emerging trend: an increase in so-called “sell-side activism” in which a company’s sell-side analysts advocate directly for change. These letters go beyond a traditional “sell” rating, instead advocating for specific, sometimes wholesale, changes at the company. more…)

article thumbnail

Uber Could Be Brewing A Plan To Enter Grocery Sector: Instacart Stock Spikes On Acquisition Whispers

Benzinga

Uber Technologies Inc (NYSE: UBER ) is reportedly considering the acquisition of grocery delivery company Instacart, according to a recent analyst report. The news has significantly impacted Instacart’s (NASDAQ: CART ) stock, which experienced a notable surge. increase in the stock price, which reached $25.48.

EBITDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 Catalysts To Drive Growth At Cisco: $28B Splunk Deal Offers 'Great Synergies,' Analyst Says

Benzinga

The stock has underperformed the market over the last 12 months mainly due to weakness in Networking. The Cisco Systems Analyst: Tal Liani upgraded the rating for Cisco Systems from Neutral to Buy, while raising the price target from $55 to $60.

article thumbnail

VIZIO Faces Analyst Downgrades Amid Walmart Acquisition, Impact On Roku

Benzinga

Shares of VIZIO Holding (NYSE: VZIO ) closed lower on Wednesday amid a series of downgrades from Wall Street analysts. JPMorgan downgraded the stock to Neutral, while raising their price target to $11.50 Craig-Hallum downgraded Vizio stock to Hold Roth MKM downgraded the stock to Neutral, lowering their price target to $11.50

52
article thumbnail

ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note

Benzinga

The ImmunoGen Analyst : Joseph Catanzaro downgraded the rating for ImmunoGen from Overweight to Neutral, while raising the price target from $24 to $31. Check out other analyst stock ratings. The deal, which is expected to close in mid-2024, represents a “great price” for ImmunoGen, at $31.26

59
article thumbnail

Zoom Valuation Reaching 'Washed-Out Levels,' Over 30% Upside Despite M&A Caution

Benzinga

After zooming through the pandemic, Zoom Video Communications (NASDAQ: ZM ) stock declined by 15% over the past year, and 13.6% The Zoom Video Analyst: JPMorgan analyst Mark R. Murphy rates the stock Neutral with a price target of $83. so far this year. It is set to report fourth-quarter earnings on Feb.

article thumbnail

Analyst Favors Exxon Mobil Deal, But Downgrades Pioneer Natural Resources: Here's Why

Benzinga

BMO Capital Markets analyst Phillip Jungwirth downgraded Pioneer Natural Resources Co (NYSE: PXD ) to Market Perform from Outperform rating. The analyst reduced the rating on its all-stock merger with Exxon Mobil Corp (NYSE: XOM ) for $59.5 billion, or $253 per share.